Hologic marks 40 years with new sustainability report, shares on NASDAQ in focus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 21:42.

Hologic (US4364401012) is using its 40th anniversary to sharpen its profile on environmental, social and governance topics. The NASDAQ-listed women’s health specialist has released its 2025 Sustainability Report alongside a recent legal victory in Europe, according to a Business Wire release and agency reports. The company’s own information

What the new report highlights

On June 17, 2026, Hologic published its 2025 Sustainability Report to coincide with the group’s 40th anniversary, emphasizing its purpose of enabling healthier lives for women globally. The report details progress on patient access, community engagement and environmental goals, according to a Business Wire dispatch distributed via Via TT. Business Wire / Via TT press release

Hologic underscores investments in women’s health screening, including breast and cervical cancer diagnostics, and outlines steps to cut operational emissions and resource use across its manufacturing footprint. The company also references initiatives that support diversity, equity and inclusion, as well as philanthropic programs in key markets such as the United States and Europe.

Patent win against Siemens in Europe

Beyond ESG, Hologic recently secured a significant patent victory in the Unified Patent Court in Germany against Siemens over mammography technology, with the decision dated June 10, 2026. The ruling covers infringement of European Patent EP 2 352 431 related to Hologic’s Focusing Technology on the Envision platform, the first FDA-approved innovation of its kind in this segment, according to agency reporting. AFP coverage of the UPC decision

The Unified Patent Court imposed an injunction that bars Siemens from making, offering, marketing, using, importing or storing its affected MAMMOMAT B.brilliant mammography systems in Germany, France and the Netherlands. The decision also mandates recall and destruction of infringing systems in those countries and provides for monetary damages and penalties in case of non-compliance, underscoring the strategic value of Hologic’s intellectual property in European breast imaging.

How Hologic earns its revenue

Hologic generates most of its revenue from diagnostics, breast and skeletal health, and surgical products, with a strong focus on women’s health screening technologies. Flagship platforms include the 3D mammography system Genius 3D Mammography and molecular diagnostic assays such as the Panther and Panther Fusion systems for human papillomavirus and other infections.

Where the stock trades today

The Hologic shares (US4364401012) trade on NASDAQ in US dollars; recent quote data place the stock around the mid-70s dollar range per share during June 2026 based on public pricing services.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research and, where appropriate, consult a licensed financial adviser.